Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934749 | 1.00 | HSD17B10 (0.46) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL33526612 | 1.00 | HSD17B10 (0.46) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL842174 | 0.95 | ATM (0.47) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL539034 | 0.88 | HSD17B10 (0.48) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL29739 | 0.88 | HSD17B10 (0.48) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL398772 | 0.88 | HSD17B10 (0.48) | HSD17B10ATMSMN1; SMN2ALDH1A1FPR3 | |
| SCHEMBL639097 | 0.86 | ATM (0.49) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL3420227 | 0.86 | ATM (0.49) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL13381365 | 0.86 | ATM (0.58) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL16983241 | 0.86 | ATM (0.58) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585460-B1 | QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8143273-B2 | Quinolizidine and indolizidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| CN-1399639-A | Novel oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | HSD17B10 1800/4885ATM 1972/4885SMN1; SMN2 1282/4885 |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | HSD17B10 1800/4885ATM 1972/4885SMN1; SMN2 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.